Novel cancer-fighting drug candidate OxaliTEX issued patents in Israel and Australia

OncoTEX Inc. is pleased to report that the notice of allowance for its OxaliTEX composition patent application, originally published on January 31, 2021, has successfully passed the opposition period and is now an issued patent.

OxaliTEX is being developed in Texas by US oncology company, OncoTEX Inc. (OncoTEX), a member of Australian bioscience enterprise The iQ Group Global, from their oncology drug platform, TEX Core.

TEX Core is a world-first oncology drug platform with the ability to develop a pipeline of novel texaphyrin-based oncology therapeutics, that are highly targeted to the tumour and that overcome toxicity, to treat a wide range of cancers.

OxaliTEX is the first TEX Core drug candidate from this new class of oncology drugs, designed to target platinum-resistant tumour cells by overcoming issues associated with the current platinum-based standard of care (SOC) and is being developed for platinum-resistant ovarian cancer.

Unlike current platinum-based SOC (standard-of-care) oncology therapeutics, OxaliTEX is tumour localising, well-tolerated, overcomes platinum-resistance, and is MRI-detectable, allowing clinicians and patients to easily monitor tumour regression during treatment.

In addition to OxaliTEX, OncoTEX has further enriched its pipeline with three additional drug candidates.

•          GemTEX (exploring the use of DNA replication inhibitors)

•          ParpTEX (exploring the use of PARP inhibitors) are part of our Chemotherapy program and

•          MangaTEX is part of our Photothermal program. 

OxaliTEX’s development is being led by OncoTEX Vice President of Research, Dr Jonathan F. Arambula via a collaboration with researchers at the University of Texas at Austin and the MD Anderson Cancer Center.

The Israel patent issuance follows our recent announcement of patent issuance in Australia.

Dr Arambula said both patents bring OncoTEX one step closer to safely and efficiently delivering life-saving medicines.

“We are enthusiastic about this patent. Having a country issue approval is a clear illustration of the innovation behind our technology and our platform,” Dr Arambula said.

“The issued patents validate our research and work and facilitates our ability to continue our development through rigorous testing, bringing us one step closer to delivering our drug to market and in the hands of clinicians.

“Our goal is to save lives, and in order to do that you need to have good technology, a good business plan and the best people by your side working day in, day out on all aspects of drug development.

“Our exclusive protection in both Australia and Israel ensures that we have the ability to develop OxaliTEX in the safest way possible for patients and healthcare providers.”

OxaliTEX is currently in pre-clinical development. As OxaliTEX addresses an unmet medical need in patients with ovarian cancer, OncoTEX intends to carry out regulatory submission via orphan drug designation following an IND submission with the FDA.

The OxaliTEX Patent Cooperation Treaty (PCT) application was first published in 2015 and has since been granted patent protection in the USA, Australia, Singapore Mexico and Israel.

More than 300,000 women globally are diagnosed with ovarian cancer each year, making ovarian cancer one of the leading causes of cancer-related death in women. This is largely because ovarian cancer is rarely symptomatic in its early stages and often untreatable and fatal by the time of detection.

About OxaliTEX

OxaliTEX is a conjugate of oxaliplatin – a well-established platinum-based chemotherapy drug – and a tumour localising metallotexaphyrin for targeted drug delivery to cancerous tumours. Preclinical studies show OxaliTEX targets solid tumour cells, activates within tumours and overcomes multi-factorial drug resistance mechanisms with minimal adverse effects and so is shown to be superior to traditional platinum-based chemotherapy drugs. Read more

About OncoTEX Inc.

OncoTEX Inc is an oncology company and member of the iQ Group Global bioscience investment enterprise The iQ Group Global. OncoTEX Inc owns TEX Core, a novel oncology drug platform that enables the development of well-tolerated, MRI-detectable cancer therapeutics that target drug-sensitive and drug-resistant solid tumours. Find out more

About The iQ Group Global

The iQ Group Global is a consortium of companies that finds, funds and develops bioscience discoveries to create life-changing medical innovations. Find out more

Media Contact

Get in touch with our media representative below.

Meet the people bringing our technology to life